Overview
- The decision, reported as the world’s first approvals for iPS‑derived products, covers Reheart for severe heart failure and Amshepri for Parkinson’s disease.
- Regulators cleared the products after confirming safety and estimating effectiveness from small trials, with obligations including all‑case tracking and use at qualified facilities by trained physicians.
- Targets call for treating about 75 patients with Reheart and 35 with Amshepri within seven years to support a move to full authorization.
- Clinical use could begin as early as this summer following pricing and national insurance reviews and after manufacturing and site readiness are in place.
- Both therapies are expected to be high‑cost, and coverage under Japan’s public insurance is anticipated pending formal deliberation, which would limit out‑of‑pocket expenses.